ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. / Morgan Hulen , Thomas ; Chamberlain, Christopher Aled; Svane, Inge Marie; Met, Özcan.

I: Immuno, Bind 1, Nr. 3, 2021, s. 194-211.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Morgan Hulen , T, Chamberlain, CA, Svane, IM & Met, Ö 2021, 'ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors', Immuno, bind 1, nr. 3, s. 194-211. https://doi.org/10.3390/immuno1030012

APA

Morgan Hulen , T., Chamberlain, C. A., Svane, I. M., & Met, Ö. (2021). ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. Immuno, 1(3), 194-211. https://doi.org/10.3390/immuno1030012

Vancouver

Morgan Hulen T, Chamberlain CA, Svane IM, Met Ö. ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. Immuno. 2021;1(3):194-211. https://doi.org/10.3390/immuno1030012

Author

Morgan Hulen , Thomas ; Chamberlain, Christopher Aled ; Svane, Inge Marie ; Met, Özcan. / ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. I: Immuno. 2021 ; Bind 1, Nr. 3. s. 194-211.

Bibtex

@article{61681732216a41948ec82b8cf22fc23b,
title = "ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors",
abstract = "The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment possibilities for cancer. Additionally, many individuals are ineligible for established immunotherapies due to their cancer type. The adoptive cell transfer of autologous tumor-infiltrating lymphocytes has been used in humans for over 30 years to treat metastatic melanoma, and continued modifications are making it increasingly more effective against other types of cancer. This comprehensive review outlines this therapy from its infancy through to the present day, bringing to light modifications and optimizations to the traditional workflow, as well as highlighting the influence of new methods and technologies. ",
author = "{Morgan Hulen}, Thomas and Chamberlain, {Christopher Aled} and Svane, {Inge Marie} and {\"O}zcan Met",
year = "2021",
doi = "10.3390/immuno1030012",
language = "English",
volume = "1",
pages = "194--211",
journal = "Immuno",
issn = "2673-5601",
publisher = "MDPI",
number = "3",

}

RIS

TY - JOUR

T1 - ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

AU - Morgan Hulen , Thomas

AU - Chamberlain, Christopher Aled

AU - Svane, Inge Marie

AU - Met, Özcan

PY - 2021

Y1 - 2021

N2 - The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment possibilities for cancer. Additionally, many individuals are ineligible for established immunotherapies due to their cancer type. The adoptive cell transfer of autologous tumor-infiltrating lymphocytes has been used in humans for over 30 years to treat metastatic melanoma, and continued modifications are making it increasingly more effective against other types of cancer. This comprehensive review outlines this therapy from its infancy through to the present day, bringing to light modifications and optimizations to the traditional workflow, as well as highlighting the influence of new methods and technologies.

AB - The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment possibilities for cancer. Additionally, many individuals are ineligible for established immunotherapies due to their cancer type. The adoptive cell transfer of autologous tumor-infiltrating lymphocytes has been used in humans for over 30 years to treat metastatic melanoma, and continued modifications are making it increasingly more effective against other types of cancer. This comprehensive review outlines this therapy from its infancy through to the present day, bringing to light modifications and optimizations to the traditional workflow, as well as highlighting the influence of new methods and technologies.

U2 - 10.3390/immuno1030012

DO - 10.3390/immuno1030012

M3 - Journal article

VL - 1

SP - 194

EP - 211

JO - Immuno

JF - Immuno

SN - 2673-5601

IS - 3

ER -

ID: 302161740